Comed Clinical Information Miranda SES
|
|
- Samson Lawrence
- 5 years ago
- Views:
Transcription
1 Technical research on Partner /Miranda Sirolimus-eluting Coronary Stent System* Yang Ming (Senior Engineer), Lepu Medical Technologies (Beijing) Co. Ltd, September 2005 This article systemetically summarized research data and analysis results of radial strength, flexibility, drug coating material and technology, and clinical trials accumulated during the research and development process of Lepu Company s Partner /Miranda drug eluting stent. A huge number of data confirm that Partner /Miranda stent has achieved an advanced level among similar products. Introduction. In the last 20 years with people s elevated living standard and increased ageing population, the incidence of coronary heart disease in China showed a significant up trend. To timely apply and promote new research findings and new techniques in clinical practice, benefiting as many patients possible, is an urgent task in the present field of cardiology. The development of percutaneous coronary intervention (PCI) represents the most outstanding advancement in the field of cardiology. The sirolimus-eluting stent launched by Johnson & Johnson Cordis Company in 2002 was another milestone in the development of percutaneous coronary intervention (PCI). A new-generation domestic sirolimus-eluting stent system launched by Lepu Company is beneficial to many coronary heart disease patients in China. We believe that, as indicated by its name, Partner / Miranda drug eluting stent will become the most loyal and reliable partner of cardiologists and heart disease centers in China. This article briefly summarized a variety of performance data accumulated during the research and development process of Partner / Miranda drug eluting stent, and compared it with drug stents produced by famous international enterprises.
2 Clinical Application of China-Made Rapamycin-Eluting System in Emergency interventional Treatment of Acute Myocardial Infarction Cheng Hui. Tu Jihong, Yan Youliang, Gao Zhaobo Department of Internal Cardiology, Third affiliated hospital of Nanchang University, Jiangxi Nanchang, China / Chinese Book Classified Number: R Literature Indentification Code: A, Article number: (2006) To investigate the safety and efficacy of China-made Rapamycin-eluting system (Partner / Miranda )* in emergency interventional treatment of acute myocardial infarction. 56 patients with AMI from November, 2005 to June 2006 were included. All patients received Emergency PCI within 12h after the onset. Immediate therapeutic effect and follow-up outcome were analyzed. Emergency interventional treatment was successful in all the 56 patients. A total of 58 Partner /Miranda were implanted. There were 3 cases of slow blood flow during the surgery. There was no severe related complication. Within 2-7 (4±2) months of follow-up, 3 patients were hospitalized because of recurrent chest pain. Two were confirmed as new lesion of other coronary branch by coronary arteriography, while the other one was in-stent restenosis and treatment by another interventional therapy. No cardiac event was found in Other patients. Out of the 56 patients, 6 patients underwent recheck and treatment by arteriography and there was no in-stent restenosis. China-made rapamycin drug-eluting system (Partner /Miranda ) was safe and effective in Emergency interventional treatment of acute myocardial infaction.
3 Partner /Miranda stents for crush technique in coronary bifurcation: Immediately and short-time follow up results. Xu-Ze Sheng, Spong Zhiyan, Ma Zengcai, et al Department of Cardiology, Changzbou Central Hospital, Changzhou, , China To estimate the security and validation of crush technique in the therapy of coronary bifurcation lesions by our national sirolimus-eluting stent (Partner /Miranda ). After coronary angiography, crush technique was used to accomplish the main branch and side branch lesions in truly bifurcation lesions (Medina type ). Six months later, coronary angiography was reexamined. There were 30 patients enrolled and total 31 of bifurcation lesions. The mean age was 61.7± 11.2 years, made was 66.7%. The 31 bifurcation lesions included: LAD-D (51.6%), LM-LAD and LCX (32.3%), RCA-PL and PD (9.7%) and LCX-OM (6.5%). The non-compliance balloon was used to expand lesions by high pressure (58.1%), finally the kissing balloon technique was completed (96.8%). The stent number in main branch and side branch vessels was 1.5±0.55 vs 1.1±0.34, the length was (37.2±1,2) mm vs (21.6±0.83) mm, the diameter was (3.27±0.51) mm vs (2.76±0.48) mm. The rate of main cardiac event (MACE) after PCI was 3.3%. It is security and validation to treat the bifurcation lesions by crush technique with Partner / Miranda Sirolimus-eluting stent, and this stent is more attractive in the therapy of complicated coronary lesions in our country because of lower fee-for-service.
4 Therapeutic Effect of Partner /Miranda Coronary Stent in the Treatment of Coronary Artery Disease and Clinical Follow-up. Huo Wong1), Li Zhangquan2), He Ben3), Chen Shaoliang4), Yu Bo, Li Kang5), Wang Dongqi7), Fu Guosheng8), Wang Ningfu8), Ma Genshan9), Ynag Zhijian10), Wang Jian an11), Shen Xiangqian12), Qi Guoxian13), Qu Peng19), Cao Xuebin14), Ma Yitong7), Li Boa15), Zheng Qiangsun16), Dong Pingshuan17), Cai Shanglong18). / 1) First Hospital of Peking University, 2) Peoples Hospital of Liaoning Provence, 3) Shanghai Renji Hospiital, 4) Nanjing First Hospital, 5) Second Affiliated Hospital of Harbin, 6) Beijing Xuanwu Hospital, 7) Affiliated Hospital of Xian Jiantong University, 8) Zhejiang Shaoyifu Hospital, 9) Jiangsu Zhongda Hospital, 10) People s Hospital of Jiangsu Province, 11) Second Affiliated Hospital of Zhejiang University, 12) Second Hospital of Hunan Xiangya Medical College, 13) First Affiliated Hospital of Chinese Medical University, 14) 252 Military Hospital, 15) Shanxi institute of cardiovascular disease, 16) Tangdu Hospital of the Forth Military Medical Univeristy, 17) First Affiliated Hospital of Henan Technology University, 18) Qingdao Medical College Affiliated Hospital, 19) Second Hospital of Dalian Medical University. To evaluate the safety and therapeutic effect of China-made Partner /Miranda coronary Stent in the treatment of coronary artery disease. Retrospectively analysis was performed on 1352 patients with coronary artery disease who were treated by insertion of Partner /Miranda coronary stents in 21 heart centers. Cardiac death, myocardial infarction, target vessel remodeling rate, main adverse cardiac event (MACE) and incidence of in-stent thrombogenesis within I year were observed. Partner /Miranda stents were inserted into 1869 lesions in 1352 patients, among were 23.3% diabetic, 90.49% were with acute coronary syndrome. Type C lesion accounted for 30.98%, branch lesion accounted for 11.13%, and chronic occlusive lesion accounted for 7.81%. Average length of target lesion vessel was 21.99±10.57 mm, average stenosis was 88.18%±10.93%, reference vessel diameter was 3.17±1.81mm, and maximum dilation pressure was 13.77± 3.01 atm. Lesion that needed pre-balloon dilation was 78.12% while lesion that needed after-balloon dilation was 25.79%. The results of follow-up showed that accumulated incidence of cardiac death, myocardial infarction, target vessel remodeling, MACE within 12 months was 0.52%, 0.96%, 2.14% and 3.62% respectively, all within acceptable range. One year accumulated incidence of thrombus (0.66%) was similar with the results od other studies. The result of one-year follow-up that China-made Partner /Miranda coronary stent had Good safety and efficacy
5 Efficacy of Partner /Miranda Stent in Patient with Coronary Heart Disease. HAO Dongqin, LIU Henliang, ZHAO Youmin, et al. Department of Cardiology, the Fifth People s Hospital of Zhengzhou, Zhengzhou , China To evaluate the effects and security of the Partner /Miranda stent (homemade Sirolimuseluting stent) in patients with coronary heart disease (CHD). Total 268 patients with CHD treated with 481 Partner /Miranda stents. Among the 268 patients, 136 were with acute myocardial infarction (AMI1) and 132 were with unstable angina. The immediate angiographic outcome, complication in the procedure, six months follow-up results, including main adverse cardiac events (MACE) and angiographic results, were assessed. A successful stenting procedure was achieved in 99.2% patients. Sub-acute in-stent thrombosis occurred in 1 patient, 2 patients died during operation and hospitalization. The MACE rate was 1.1% during hospitalization and 2.3% during 6 months follow-up. At 6 months, angiographic results showed that in-stent restenosis rate (ISR) was 5.4%. The target vessel revascularization rate was 5.4%. Partner /Miranda stent implantation in patients with CHD is safe and effective, the ISR rate and TLR rate are significantly lower than those of bare metal stents.
6 Short-term clinical observation of the domestic and the imported rapamycin-eluting Stent Wei Wenbing, The Cardiovascular Internal Medicine Department of the Shenzhen Futian People s Hospital, Shenzhen of Guangdong, Zip Code The objective was to investigate the difference in therapeutic effects of the domestic and Imported rapamysin-eluting stent. The paper concluded 107 patients of coronary arteriosclerotic heart disease with Cypher and Partner /Miranda stent implantation since year 2006 in our hospital. When comparing the general statuses of the two groups, p-values were both > 0.05 and showed no statistical significance. As for the characteristics of target blood vessels in the Two groups of patients, p-values was > 0.05 and showed no statistical significance. When comparing the average target vascular diameter and the average target lesion length In the Cypher group and the Partner /Miranda group, they showed Cypher ( mm) vs Partner /Miranda ( mm) and Cypher ( mm) and Partner / Miranda ( mm). The p-values were > 0.05 and showed no statistical significance. Clinical follow-up lasted 6 months, where both groups of patients did not develop acute and Subacute intra-stent thrombosis, as well as recurrence of myocardial infarction and death. In comparison of primary cardiovascular events, recurrence of pectoris angina, and vascular Reconstruction, p-values were all > 0.05 without statistical significance. Domestic and imported rapamycin-eluting stents have similar short-term therapeutic effects.
7 Comparison between Partner /Miranda and Cypher rapamycin drug-eluting stent in The treatment of coronary artery disease. Gao Kang, Yang Ming, Wang Qing, Pab Guozhing, Han Ling, Chen Liwei, Cen Qiang., Cardiovasology Center in Hu Xing Hospital, Capital Medical University / Chinese Book Classificatioin Number R541.4, Literature Indentification Code A, Article Number (2007) To compare the manipuility, safety and efficacy of Partner /Miranda and Cypher in clinical application. Retrospective analysis was performed on Partner /Miranda stents which were used from February 2006 to November 2006 in the Cardiovasology Center in Hu Xing Hospital, Capital Medical University. Clinical application during the surgery and within half a year after the surgery was analyzed and compared with that of Cypher stent used in the same period. 1) There were 57 patients in Cypher stent group and 48 patients in the Partner /Miranda stent group. There was no statistical significant difference in number of branches involved. of intervention or average length of stent implanted between the two groups. Both post-operative minimum lumen diameter (MLD) and stenosis were significantly improved. There was significant difference in treatment of intermediated branch lesion, stent diameter and surgery cost, 2) 6 month follow-up completion rate was similar between the two groups. Incidence of major adverse cardiac events within 6 months after the surgery was similar between the two groups. There was no statistical significant difference in incidence of MACE, in-stent restenosis, in-stent thrombosis, non-lethal myocardial infarction, or target vessel revascularization between the two groups within 6 months after the surgery. Partner /Miranda stent was safe and effective in the treatment of coronary artery disease. Its relatively low cost made it more attractive in the clinical application in China.
8 Study of sixty two cases of left main coronary artery disease treated with Partner / Miranda DES Zhao Yan, Zhang Yun-mei, Zhang Hong, The First People s Hospital of Yunna Province, Kunming, To evaluate the clinic outcomes of left main artery disease treated with Partner /Miranda drug-eluting stent. August 2005 to April 2007, 62 patients with left main artery disease undergone percutaneous coronary intervention (PCI), and 102 Partner /Miranda stents were implanted. All patients were followed-up for 1-2 years, restenosis, cardiac events and death were analyzed. 102 stents were implanted in 62 patients. Among them 34 patients treated with step crush technique, 3 patients occurred with restenosis and 1 patient with AMI. Partner /Miranda stent is effective in treatment of left main artery disease, double stent is independent risk factor of restenosis.
9 Overlapping Homemade Partner /Miranda vs Cypher Sirulimus Eluting Stents to Treat Diffuse Disease of Coronary Artery Wang Lei, Wang Ming-sheng, Wang He, et al. Department of Cardiology, Beijing Shijingshan Hospital Beijing, 10043, China To evaluate the efficacy of overlapping homemade Partner /Miranda vs Cypher sirolimus eluting stent to treat diffuse disease of coronary arterial lesions. From January 2005 to January 2008, 128 patients with diffuse de novo coronary lesions underwent overlapping homemade Partner /Miranda sirolimus eluting stent therapy were matching with the other 104 patients receiving overlapping Cypher sirolimus eluting stents therapy. Clinically characteristics and follow-up results were compared between the two groups. Partner /Miranda stent group had more three-vessel lesion and hyperlipoidemia patients, the rest aspects of baseline features in the two groups were similar. 1-year and 2-year followup were all similar Overlapping homemade Partner /Miranda sirolimus eluting stents in patients with a diffuse coronary arterial lesion is relatively safe and associated with good clinical outcomes.
10 Clinical Application of Partner /Miranda Drug Eluting Stent Huang Bin, Li Xin, Bal Jing, Qin Longfei, Shen Hang. Department of Interventional Therapy, Zhengzhou University Fifth Affiliated Hospital, Hennan Zhengzhou, To investigate the therapeutic effect and safety of Partner /Miranda drug-eluting stent. 111 patients with coronary artery disease were treated percutaneous coronary intervention with Partner /Miranda drug-eluting stent from January 2006 to December All patients were followed-up after the surgery to observe the recurrence of chest pain, changes in electrocardiogram and occurrence of major adverse cardiac events. A total of 196 Partner /Miranda drug eluting stents were implanted in 180 lesions in 111 patients. Surgery success rate was 100%. There was no recurrence of chest pain and there was no major adverse cardiac event after surgery. The short-term therapeutic effect of Partner /Miranda rapamycin drug-eluting stent in PCI was satisfying. Its application was safe and convenient.
11 Effect of Rapamycin Eluting Stent on Level of C-reactive Protein in Patients with Acute coronary Syndrome After Angioplasty. CHEN Hui, Tu-Xie-hiong, YAN You-liang, GAO Zhao-bo. Department of Cardiology, The Third Affiliated Hospital of Nanchang Universtity, Nanchang , China. To compare the effect of domestic produced rapamycin eluting stents (Partner /Miranda ) versus conventional stainless steel stent on the levels of C-reactive protein (CRP) in the patients with acute coronary syndrome after angioplasty. A total of 68 cases of acute coronary syndrome were randomly divided into group A (n=36) and group B (n=32). The patients in group A received domestic produced rapamycin eluting Stent (Partner /Miranda ) while the patients in group B received conventional stainless steel stent. Venous blood samples were taken before, at 12 and 24 hours after angioplasty in both groups, and serum samples were analyzed for CRP by particle-enhanced immumoturbidimetry. Result At before percutaneous transluminal coronary angioplasty, the levels of CRP has no statistical significant difference between the two groups (P > 0.05). At 12 and 24 hours after angioplasty, the levels of CRP has statistical significant difference between the two groups (P < 0.05). Domestic produced rapamycin eluting stent (Partner /Miranda ) could decrease the levels of CRP and possibly suppress inflammatory reaction in the patients with acute coronary syndrome after angioplasty.
12 The long-term outcomes of the patients with coronary heart disease treated by domestic Partner /Miranda coronary stent. Clinical centers and main investigators involved were: Huo Yong, Chen Ming and Li Jianping from First Hospital of Peking University, Li Zhanquan from the People s Hospital of Liaoning Province, He Ben from Shanghai Renji Hospital, Chen Shaoliang from Nanjing First Hospital, Yu Bo from Second Affiliated Hospital of Harbin, Li Kang from Beijing Xuanwu Hospital, Wang Dongqi from Affiliated Hospital of Xian Jiatong University, Fu Guosheng from Zhejiang Shaoyifu Hospital, Wang Ningfu from Hangzhou First Hospital, Ma Gensham from Jiangsu Zhingda Hospital, Yang Zhijian from the People s Hospital Jiangsu Province, Wang Jianan from the Second Affiliated Hospital of Zhejiang University, Shen Xiangqian from the Second Affiliated Hospital of Hunan Xiangya Medical College, Qi Guoxian and Jia Dalin from the First Affiliated Hospital of Chinese Medical University, Qu Peng from the Second Hospital of Dalian Medical University, Cao Xuebin and Mu Xianyou from the 252 Military Hospital, Ma Yitong from the First Affiliated Hospital of Xinjiang Medical Univerisity, Li Bao from Shanxi Institute of Cardiovascular Disease, Zheng Qiangsum from Tangdu Hospital of the Forth Military Medical University, Deng Pingshuan from the First Affiliated Hospital of Henan Technology University, Cai Shanglang from Qingdao Medical College Affiliated Hospital. To evaluate the safety and efficacy of domestic Partner /Miranda stent in treating coronary artery disease. The 24 month follow-up results of Partner /Miranda coronary stent implantation in 1352 coronary heart disease (CHD) patients were retrospectively analyzed in 21 medical centers. Implantation of 1869 Partner /Miranda coronary stents was successfully performed in 1352 patients. 12 months cumulative cardiac death rate (0.52%), Myocardial Infarction (0.96%), TVR (2,14%), MACE (3.62%); 24 months cumulative cardiac death rate (0.81%), Myocardial Infarction (2.07%), TVR (3.70%), MACE (6.58%) is acceptable and comparable with imported coronary stents. Domestic Partner /Miranda coronary stent can be safely implanted in severe CHD patients with ideal long-term outcomes.
13 Bibliography 1)Technical research on Partner /Miranda Sirolimus-eluting Coronary Stent System* Yang Ming (Senior Engineer), Lepu Medical Technologies (Beijing) Co. Ltd, September ) Clinical Application of China-Made Rapamycin-Eluting System in Emergency interventional Treatment of Acute Myocardial Infarction Cheng Hui. Tu Jihong, Yan Youliang, Gao Zhaobo. Department of Internal Cardiology, Third affiliated hospital of Nanchang University, Jiangxi Nanchang, China / Chinese Book Classified Number: R Literature Indentification Code: A, Article number: (2006) ) Partner /Miranda stents for crush technique in coronary bifurcation: Immediately and short-time follow up results. Xu-Ze Sheng, Spong Zhiyan, Ma Zengcai, et al. Department of Cardiology, Changzbou Central Hospital, Changzhou, , China 4) Therapeutic Effect of Partner /Miranda Coronary Stent in the Treatment of Coronary Artery Disease and Clinical Followup. Huo Wong1), Li Zhangquan2), He Ben3), Chen Shaoliang4), Yu Bo, Li Kang5), Wang Dongqi7), Fu Guosheng8), Wang Ningfu8), Ma Genshan9), Ynag Zhijian10), Wang Jian an11), Shen Xiangqian12), Qi Guoxian13), Qu Peng19), Cao Xuebin14), Ma Yitong7), Li Boa15), Zheng Qiangsun16), Dong Pingshuan17), Cai Shanglong18). / 1) First Hospital of Peking University, 2) Peoples Hospital of Liaoning Provence, 3) Shanghai Renji Hospiital, 4) Nanjing First Hospital, 5) Second Affiliated Hospital of Harbin, 6) Beijing Xuanwu Hospital, 7) Affiliated Hospital of Xian Jiantong University, 8) Zhejiang Shaoyifu Hospital, 9) Jiangsu Zhongda Hospital, 10) People s Hospital of Jiangsu Province, 11) Second Affiliated Hospital of Zhejiang University, 12) Second Hospital of Hunan Xiangya Medical College, 13) First Affiliated Hospital of Chinese Medical University, 14) 252 Military Hospital, 15) Shanxi institute of cardiovascular disease, 16) Tangdu Hospital of the Forth Military Medical Univeristy, 17) First Affiliated Hospital of Henan Technology University, 18) Qingdao Medical College Affiliated Hospital, 19) Second Hospital of Dalian Medical University. 5) Efficacy of Partner /Miranda Stent in Patient with Coronary Heart Disease. HAO Dongqin, LIU Henliang, ZHAO Youmin, et al. Department of Cardiology, the Fifth People s Hospital of Zhengzhou, Zhengzhou , China 6) Short-term clinical observation of the domestic and the imported rapamycin-eluting Stent Wei Wenbing, The Cardiovascular Internal Medicine Department of the Shenzhen Futian People s Hospital, Shenzhen of Guangdong, Zip Code ) Comparison between Partner /Miranda and Cypher rapamycin drug-eluting stent in The treatment of coronary artery disease. Gao Kang, Yang Ming, Wang Qing, Pab Guozhing, Han Ling, Chen Liwei, Cen Qiang., Cardiovasology Center in Hu Xing Hospital, Capital Medical University / Chinese Book Classification Number R541.4, Literature Indentification Code A, Article Number (2007) ) Study of sixty two cases of left main coronary artery disease treated with Partner /Miranda DES Zhao Yan, Zhang Yun-mei, Zhang Hong, The First People s Hospital of Yunna Province, Kunming, ) Overlapping Homemade Partner /Miranda vs Cypher Sirulimus Eluting Stents to Treat Diffuse Disease of Coronary Artery Wang Lei, Wang Ming-sheng, Wang He, et al. Department of Cardiology, Beijing Shijingshan Hospital Beijing, 10043, China 10) Clinical Application of Partner /Miranda Drug Eluting Stent Huang Bin, Li Xin, Bal Jing, Qin Longfei, Shen Hang. Department of Interventional Therapy, Zhengzhou University Fifth Affiliated Hospital, Hennan Zhengzhou, ) Effect of Rapamycin Eluting Stent on Level of C-reactive Protein in Patients with Acute coronary Syndrome After Angioplasty. CHEN Hui, Tu-Xie-hiong, YAN You-liang, GAO Zhao-bo. Department of Cardiology, The Third Affiliated Hospital of Nanchang Universtity, Nanchang , China. 12) The long-term outcomes of the patients with coronary heart disease treated by domestic Partner /Miranda coronary stent. Clinical centers and main investigators involved were: Huo Yong, Chen Ming and Li Jianping from First Hospital of Peking University, Li Zhanquan from the People s Hospital of Liaoning Province, He Ben from Shanghai Renji Hospital, Chen Shaoliang from Nanjing First Hospital, Yu Bo from Second Affiliated Hospital of Harbin, Li Kang from Beijing Xuanwu Hospital, Wang Dongqi from Affiliated Hospital of Xian Jiatong University, Fu Guosheng from Zhejiang Shaoyifu Hospital, Wang Ningfu from Hangzhou First Hospital, Ma Gensham from Jiangsu Zhingda Hospital, Yang Zhijian from the People s Hospital Jiangsu Province, Wang Jianan from the Second Affiliated Hospital of Zhejiang University, Shen Xiangqian from the Second Affiliated Hospital of Hunan Xiangya Medical College, Qi Guoxian and Jia Dalin from the First Affiliated Hospital of Chinese Medical University, Qu Peng from the Second Hospital of Dalian Medical University, Cao Xuebin and Mu Xianyou from the 252 Military Hospital, Ma Yitong from the First Affiliated Hospital of Xinjiang Medical Univerisity, Li Bao from Shanxi Institute of Cardiovascular Disease, Zheng Qiangsum from Tangdu Hospital of the Forth Military Medical University, Deng Pingshuan from the First Affiliated Hospital of Henan Technology University, Cai Shanglang from Qingdao Medical College Affiliated Hospital.
Run-Lin Gao, MD, FACC. On Behalf of I-LOVE-IT Trial Investigators
I-LOVE-IT A Prospective, Multicenter Clinical Trial of TIVOLI Bioabsorbable Polymer Based Sirolimus-Eluting vs. ENDEAVOR Zotarolimus- Eluting Stent in Patients with Coronary Artery Disease: 8-Month Angiographic
Abstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
Firebird stent for the treatment of patients with coronary heart disease: short-term clinical outcome
Journal of Geriatric Cardiology September 2009 Vol 6 No 3 157 Clinical Research Firebird stent for the treatment of patients with coronary heart disease: short-term clinical outcome Hai-Ying Wang, 1 Jin-Bo
Clinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
Phase IV clinical trial of Shufeng Jiedu Capsule in the treatment of cases of acute upper espiratory infection of wind-heat syndrome
tp tp Phase IV clinical trial of Shufeng Jiedu Capsule in the treatment of 2 031 cases of acute upper espiratory infection of wind-heat syndrome XU Yan-ling 1, ZHANG Hui-hong 2, XUE Yun-li 2, YANG Jing-sheng
Bifurcations Bad Krozingen I
Bifurcations Bad Krozingen I Clinical outcome 5 years after routine T-Stenting versus provisional T-stenting in the treatment of de novo coronary bifurcation lesions using sirolimus-eluting stents M. Ferenc
Percutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
FFR-guided Jailed Side Branch Intervention
FFR-guided Jailed Side Branch Intervention - Pressure wire in Bifurcation lesions - Bon-Kwon Koo, MD, PhD Seoul National University Hospital, Seoul, Korea Bifurcation Lesions Bifurcation Lesions Still
LM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer
Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time
Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54
CORRECTION NOTICE Nat. Genet. 42, 759 763 (2010); published online 22 August 2010; corrected online 27 August 2014 Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
Unprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
Non-LM bifurcation studies of importance in 2011
7th European Bifurcation Club 14-15 October 2011 LISBON Goran Stankovic MD, PhD Non-LM bifurcation studies of importance in 2011 October 15 th : 08:00 08:10 DKCRUSH-II: A Prospective Randomized Trial of
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions
Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large
MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION
MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides Euromedica Kyanous Stavros, Thessaloniki.
Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent. Masahiko Ochiai MD, FACC, FESC, FSCAI
Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent Masahiko Ochiai MD, FACC, FESC, FSCAI Division of Cardiology and Cardiovascular Surgery Showa University Northern Yokohama Hospital
A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.
A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.
Conflict of interest :None. Meta-analysis. Zhangwei Chen, MD
Meta-analysis Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation Zhangwei Chen, MD Department of Cardiology,
Insight from the CACTUS trial Coronary Bifurcation Application of the Crush
EBC - Prague 26-28 september 2008 Insight from the CACTUS trial The role of final kissing balloon inflation F. Airoldi,, A. Colombo San Raffaele Scientific Institute EMO Centro Cuore,, Columbus Hospital
PCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
PCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
General Report on Clinical Trial of. Sirolimus-eluting Coronary Stent System
General Report on Clinical Trial of AFFINITY Sirolimus-eluting Coronary Stent System PRODUCT NAME: Sirolimus-eluting Coronary Stent System TRADE NAME: AFFINITY Sirolimus-eluting Coronary Stent System SPECIFICATION:
PCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
Sunao Nakamura M.D,Ph.D.
Drug Eluting Stent Implantation For Unprotected Left ain Coronary Arteries New Tokyo Circulation Research Group New Tokyo Hospital Sunao Nakamura.D,Ph.D. Drug-Eluting Stent for Left ain Coronary Artery
Sirolimus Nanocrystal Balloon Based Delivery for Coronary DES ISR
Sirolimus Nanocrystal Balloon Based Delivery for Coronary DES ISR DR. SAMEER I DANI Director, Department of Cardiology, Apollo Hospital & Life Care Institute (LIMSAR), Ahmedabad, India. IN STENT RESTENOSIS
The MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
Bifurcation stenting with BVS
Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have
ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April Session: Left mains & bifurcation intervention
ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC Seoul, Korea: 25-27 27 April 2007 Session: Left mains & bifurcation intervention An integrated approach to bifurcation lesions: lessons from years of randomized
Count Down to COMBAT
Count Down to COMBAT Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease Roxana Mehran, MD Associate Professor of
Journal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
Available online International Journal of Pharmaceutical Research & Allied Sciences, 2017, 6(1):
Available online www.ijpras.com International Journal of Pharmaceutical Research & Allied Sciences, 2017, 6(1):107-112 Research Article ISSN : 2277-3657 CODEN(USA) : IJPRPM Research on the Clinical Phenotype
Ruofei Jia, Zening Jin, Hong Li, Jing Han. Introduction
Case Report Re-crossing the distal cell in bifurcation verified by using an enhanced stent visualization system and optical coherence tomography: a report of two cases Ruofei Jia, Zening Jin, Hong Li,
The Vascular Concepts - PRONOVA Durable Polymer Sirolimus Eluting Stent A Review of Indian Registry Results
The Vascular Concepts - PRONOVA Durable Polymer Sirolimus Eluting Stent A Review of Indian Registry Results Dr. VIVEK GUPTA MD, DM, FICC, FIC France Senior Interventional Cardiologist Indraprastha Apollo
A 4-year study of Red Yeast Rice extract known as Xuezhikang which lowers cholesterol... Monday, July 27, 2009
A 4-year study of Red Yeast Rice extract known as Xuezhikang which lowers cholesterol... 1 At a dose of 600 mg twice a day... 2 Reduced coronary events by 37%... 3 Reduced death from coronary heart disease
Integrated Use of IVUS and FFR for LM Stenting
Integrated Use of IVUS and FFR for LM Stenting Gary S. Mintz, MD Cardiovascular Research Foundation Four studies have highlighted the inaccuracy of angiography in the assessment of LMCA disease Fisher
Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement
Post PCI functional testing and imaging: case based lessons from FFR React
Post PCI functional testing and imaging: case based lessons from FFR React Joost Daemen, MD, PhD, FESC Optics in Cardiology 2018 April 21st, 2018 10.15 10.30h Disclosure Statement of Financial Interest
Sirolimus-Eluting Stents for Treatment of In-Stent Restenosis
Clinical Investigation Alfonso Medina, MD José Suárez de Lezo, MD Manuel Pan, MD Antonio Delgado, MD José Segura, MD Djordje Pavlovic, MD Francisco Melián, MD Miguel Romero, MD Federico Segura, MD Enrique
STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on
Making the difference with Live Image Guidance
Interventional Cardiology AlluraClarity Making the difference with Live Image Guidance Diagnosis and treatment of coronary artery diseases and atherosclerosis Where/who The First Bethune Hospital of Jilin
Protection of side branch is essential in treating bifurcation lesions: overview
Angioplasty Summit TCT Asia Pacific Seoul, April 26-28, 2006 Protection of side branch is essential in treating bifurcation lesions: overview Alfredo R Galassi, MD, FACC, FSCAI, FESC Head of the Catetherization
Research Article Systematic Review of Chinese Herbal Medicines for Preventing in-stent Coronary Restenosis after Percutaneous Coronary Intervention
Evidence-Based Complementary and Alternative Medicine Volume 2012, Article ID 253409, 19 pages doi:10.1155/2012/253409 Research Article Systematic Review of Chinese Herbal Medicines for Preventing in-stent
CURRICULUM VITAE Shanshan Zhou. Shanshan Zhou. Department of Cardiology. Tel: Feb 25, 1982, China. Chinese.
CURRICULUM VITAE Shanshan Zhou PERSONAL DETAILS Name: Work address: Shanshan Zhou Department of Cardiology The General Hospital of the People's Liberation Army 28 Fuxing Road, Haidian District, Beijing,
Prevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
Biodegradable Stents An update and work-in
Biodegradable Stents An update and work-in in-progress Department of Cardiology, Hideo Tamai, M.D. Metallic stents... Background induce a varing degree of thrombogenesis eg, subacute thrombosis in complex
EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb
EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb A. Medina Servicio de Cardiología Hospital Universitario de Gran Canaria Dr. Negrín Islas Canarias (Spain) Provisional
Key Words Angioplasty Coronary artery disease Revascularization Stent drug eluting stent
J Cardiol 26 Dec; 48 6 : 325 331 3 mm : Initial and Mid-Term Effects of 3 mm Long Sirolimus-Eluting Stents in Patients With Diffuse Long Coronary Lesions: Comparison With Bare Metal Stents Abstract Yosuke
C. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller
Paclitaxel-Eluting PTCA-Balloon in Combination with the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease C. W. Hamm, B. Cremers, H. Moellmann,
Rationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
PCI for Bifurcation Coronary Lesion
PCI for Bifurcation Coronary Lesion Bifurcation Lesions PCI is Challenging Higher acute complication Lower success rates Higher restenosis & TLR Restenosis Rate 21 ~ 57% TLR 8 ~ 43% Event Free Survival
Drug eluting balloons in CAD
Drug eluting balloons in CAD Ioannis Iakovou, MD, PhD Interventional Cardiology 1 st Cath Lab Onassis Cardiac Surgery Center Drug-Eluting Balloons (DEB) Technology and Applications 1. Special Features
For Personal Use. Copyright HMP 2013
Case Report J INVASIVE CARDIOL 2013;25(2):E39-E41 A Case With Successful Retrograde Stent Delivery via AC Branch for Tortuous Right Coronary Artery Yoshiki Uehara, MD, PhD, Mitsuyuki Shimizu, MD, PhD,
Seasonal and geographical dispersal regularity of airborne pollens in China LI Quan-sheng, JIANG Sheng-xue, LI Xin-ze, ZHU Xiao-ming, WEI Qing-yu *
Med J Chin PLA, Vol. 42, No. 11, November 1, 2017 951 [] [ ] [ ] R562.25[ ] A[] 0177-7402(2017)11-0951-05 [DOI] 10.11855/j.issn.0577-7402.2017.11.03 Seasonal and geographical dispersal regularity of airborne
Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες
Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)
Stent Thrombosis in Bifurcation Stenting
Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,
Drug Eluting Stents: Bifurcation and Left Main Approach
TCT Asia 2006 Drug Eluting Stents: Bifurcation and Left Main Approach Eberhard Grube MD FACC, FSCAI Heart Center,, Germany Stanford University, School of Medicine, CA, USA DES in High Risk Lesions TAXUS
PROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
Chinese Medical Journal 2008; 121(17): administered before the procedure. Results of coronary angiography and PCI procedures were assess
1670 Original article Long term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years ZHANG Qi, XU Bo, YANG Yue-jin, QIAO Shu-bin,
Medtronic Symposium The Complex Bifurcation Patient: new insights into stent selection
Medtronic Symposium The Complex Bifurcation Patient: new insights into stent selection Carlo Trani, MD, FESC Cardiology Department, Catholic University of the Sacred Heart, Rome - Italy How would you treat
Bioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals
Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for
Normal Reference Value of Hemoglobin of Middleaged Women and Altitude
YALE JOURNAL OF BIOLOGY AND MEDICINE 77 (2004), pp. 117-123. Copyright 2005. All rights reserved. ORIGINAL CONTRIBUTION Normal Reference Value of Hemoglobin of Middleaged Women and Altitude Ge Miao, a,*
Formation of and countermeasures for subacute coronary stent thrombosis in elderly diabetic patients
Formation of and countermeasures for subacute coronary stent thrombosis in elderly diabetic patients Z.-F. Li 1, Y.-P. Zhang 2, Z.-Q. Qin 2, X.-L. Li 1, C.-H. Gao 1, S. Yang 1 and Z.-J. Chen 1 1 Department
IN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
Drug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester
Drug eluting stents Where are we now and what can we expect in 2003? Tony Gershlick Leicester Trials Real World What we need i. Prevent restenosis cost effective Either : - Treat all at equivalent cost
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center, Athens, Greece Critical issues in LM PCI Anatomic variability Techniques Variability
Summary HTA. Drug-eluting stents vs. coronary artery bypass-grafting. HTA-Report Summary. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A
Summary HTA HTA-Report Summary Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease Gorenoi V, Dintsios CM, Schönermark MP, Hagen A Scientific background The coronary heart
INDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
Coronary drug-eluting stents (DES) were first approved
Thrombosis in Coronary Drug-Eluting Stents Report From the Meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health,
Rapid Detection of Milk Protein based on Proteolysis Catalyzed by Trypsinase
Rapid Detection of Milk Protein based on Proteolysis Catalyzed by Trypsinase Yafeng Chen Institute of Food Quality and Safety, University of Shanghai for Science and Technology Shanghai 93, China Email:cyfxy498@6.com
Perioperative Management After Coronary Stenting: Risk Assessment Before Surgery. Christian Seiler No conflict of interest to declare.
Perioperative Management After Coronary Stenting: Risk Assessment Before Surgery Christian Seiler No conflict of interest to declare PCI Long-Term Outcome Perioperative Management After Coronary Stenting:
Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland
Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data
Korea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea
Left Main Disease versus Non Left Main Disease in Acute Myocardial Infarction Patients in Real world Clinical Practice : Lessons from Korea Acute Myocardial Infarction Registry (KAMIR) Seung-Woon Rha*,
ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries
ANGIOPLASY SUMMIT 007 TCT ASIA PACIFIC Seoul, Korea: 5-7 7 April 007 15 min Plenary Session: State-of of-the-art Lectures The problem is exaggerated: Data from Real World Registries Antonio Colombo Centro
Contemporary therapy of bifurcation lesions
Contemporary therapy of bifurcation lesions Dr Angela Hoye MB ChB PhD MRCP Interventional Cardiologist Kingston-upon-Hull, UK Hull The challenge of bifurcations Risk of peri-procedural infarction Relatively
Review Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting Stents: A Meta-Analysis
International Scholarly Research Network ISRN Cardiology Volume 2011, Article ID 675638, 6 pages doi:10.5402/2011/675638 Review Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting
A Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations
Innovative Devices : Non Stent Technologies : Drug Eluting Balloons A Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations Pieter R. Stella, MD Director CardioVascular Research
Zotarolimus- and Paclitaxel-Eluting Stents in an All-Comer Population in China
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 6, NO. 7, 2013 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2013.03.001
Canqiu Yu 1, Jinwei Chen 2, Li Huang 3*
A STUDY ON THE ANTITUMOUR EFFECT OF TOTAL FLAVONOIDS FROM PTERIS MULTIFIDA POIR IN H22 TUMOUR-BEARING MICE 459 Canqiu Yu 1, Jinwei Chen 2, Li Huang 3* 1 Department of General Surgery, The Second Xiangya
in an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore
Unrelenting Left Main Disease in an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore Clinical History 72 years old Chinese lady Background and CV Risk
Important LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
Chinese Medical Journal 2008; 121(6): TM stent in treating patients with CAD. METHODS Study design and patient selection The design and d
492 Original article Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2 TM stent XU Bo, ZHANG Qi, YANG Yue-jin, QIAO Shu-bin, ZHANG Rui-yan, ZHANG
Catch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
Stent Fracture and Longitudinal Compression on CT Angiography between the
2014 ASCI Stent Fracture and Longitudinal Compression on CT Angiography between the First- and New-Generation Drug-Eluting Stent Mi Sun Chung, Dong Hyun Yang,Young-Hak Kim, Jae-Hyung Roh, Joon-Won Kang,
eucalimus - First Experience
A New Sirolimus Eluting Stent with a Biodegradable Polymer Early and Mid Term Experience with the eucalimus Stent in Egypt Dr. Hossam El Din Mohamed Mansour on behalf of the investigators Ahmed Emara,
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
The Spectrum of Dedicated Stents for Bifurcation Lesions: Current Status and Future Projections. Martin B. Leon, MD
The Spectrum of Dedicated Stents for Bifurcation Lesions: Current Status and Future Projections Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New York City Angioplasty
Lessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
Evolution In Interventional Cardiology. Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands
Evolution In Interventional Cardiology Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands 25 November 2010 Coronary Atherosclerosis Timeline in interventional cardiology Indications for
DESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or